Indivior Pharmaceuticals, Inc. Auditor
The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.
- 2026-03-02: Fiscal year end 2025-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location Baltimore, Maryland.
- 2025-02-25: Fiscal year end 2024-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location Baltimore, Maryland.
- 2024-02-27: Fiscal year end 2023-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location Baltimore, Maryland.
- 2023-03-09: Fiscal year end 2022-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location Baltimore, Maryland.
| Filed | Fiscal year end | Auditor | PCAOB firm ID | Location | Internal-control attestation |
|---|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | KPMG LLP | 185 | Baltimore, Maryland | Yes |
| 2025-02-25 | 2024-12-31 | KPMG LLP | 185 | Baltimore, Maryland | Yes |
| 2024-02-27 | 2023-12-31 | KPMG LLP | 185 | Baltimore, Maryland | Yes |
| 2023-03-09 | 2022-12-31 | KPMG LLP | 185 | Baltimore, Maryland | Yes |
| 2022-04-13 | 2021-12-31 | KPMG LLP | 185 | Baltimore, Maryland | Yes |
| 2021-03-08 | 2020-12-31 | KPMG LLP | Baltimore, Maryland | Yes | |
| 2020-02-28 | 2019-12-31 | KPMG LLP | Baltimore, Maryland | ||
| 2019-03-01 | 2018-12-31 | KPMG LLP | |||
| 2018-03-01 | 2017-12-31 | KPMG LLP | |||
| 2017-03-16 | 2016-12-31 | KPMG LLP | |||
| 2017-01-20 | 2015-12-31 | KPMG LLP | Baltimore, Maryland | ||
| 2016-03-09 | 2015-12-31 | KPMG LLP | |||
| 2015-03-12 | 2014-12-31 | Ernst & Young LLP | |||
| 2014-03-21 | 2013-12-31 | Ernst & Young LLP | |||
| 2013-03-15 | 2012-12-31 | Ernst & Young LLP |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |